Which of the following is NOT a cardinal sign of inflammation?
What is the shelf life of blood preserved with CPDA?
An oval lesion is found in the right lobe of the liver in an otherwise asymptomatic 24-year-old female. Surgical resection finds a single well-demarcated lesion that has a prominent, central, stellate white scar. What is the most consistent diagnosis based on this gross appearance?
Liquefactive necrosis is typically seen in which organ?
Papillary cystadenoma lymphomatosum is otherwise called:
What is the term for a dilated endoplasmic reticulum?
A cyst showing cholesterol crystals is/are:
Dystrophic calcification is seen in which of the following conditions?
The execution phase of apoptosis, which mediates the final phase of programmed cell death, is associated with which of the following caspases?
CD-95 has a major role in:
Explanation: **Explanation:** The cardinal signs of inflammation were first described by **Cornelius Celsus** in the 1st century AD [1]. These signs represent the clinical manifestation of the underlying vascular and cellular changes occurring in the tissue. **Why Cyanosis is the Correct Answer:** Cyanosis refers to a bluish discoloration of the skin or mucous membranes caused by an increase in deoxygenated hemoglobin. It is typically a sign of hypoxia or circulatory failure, not inflammation. In acute inflammation, the primary vascular change is **vasodilation** [2], which leads to increased blood flow (hyperemia), resulting in redness, not blueness [1]. **Analysis of Incorrect Options:** * **Redness (Rubor):** Caused by vasodilation and increased blood flow to the inflamed area [1]. * **Swelling (Tumor):** Result of increased vascular permeability leading to the accumulation of exudate (fluid and proteins) in the extravascular space [2]. * **Pain (Dolor):** Caused by the release of chemical mediators like **Bradykinin** and **Prostaglandins (PGE2)** [3], which sensitize nerve endings, as well as physical pressure from edema. **High-Yield Clinical Pearls for NEET-PG:** 1. **The Five Cardinal Signs:** Celsus described four (Rubor, Tumor, Calor, Dolor). The fifth sign, **Functio Laesa** (Loss of function), was later added by **Rudolf Virchow** [1]. 2. **Heat (Calor):** Also due to increased blood flow and elevated local metabolic activity [1]. 3. **Key Mediator of Pain:** Bradykinin is the most potent pain-producing substance in the inflammatory soup [3]. 4. **Key Mediator of Fever:** Interleukin-1 (IL-1) and TNF-alpha act on the hypothalamus to induce fever [3]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 185-186. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 84-85. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, p. 101.
Explanation: **Explanation:** The shelf life of stored blood is determined by the anticoagulant-preservative solution used, which maintains red cell viability and prevents clotting. **CPDA-1 (Citrate Phosphate Dextrose Adenine)** is the most commonly used conventional preservative. * **Why 5 weeks is correct:** CPDA-1 extends the storage life of whole blood or packed red blood cells (PRBCs) to **35 days (5 weeks)**. The addition of **Adenine** is the key factor here; it provides a substrate for red cells to synthesize ATP, which maintains membrane integrity and improves post-transfusion survival compared to older solutions. **Analysis of Incorrect Options:** * **A & B (2-3 weeks):** These durations are associated with older preservatives like **ACD (Acid Citrate Dextrose)** or **CPD (Citrate Phosphate Dextrose)**, which lack adenine and only preserve blood for 21 days. * **D (8 weeks):** This exceeds the capability of CPDA-1. However, storage can be extended to **42 days (6 weeks)** if **Additive Solutions** (like SAGM: Saline, Adenine, Glucose, and Mannitol) are used. **High-Yield Clinical Pearls for NEET-PG:** * **Storage Temperature:** Blood must be stored at **2°C to 6°C**. * **The "Storage Lesion":** During storage, certain changes occur (decreased pH, decreased 2,3-DPG, decreased Sodium, and **increased Potassium**). * **Fresh Blood:** Defined as blood stored for <7 days; preferred in exchange transfusions to avoid hyperkalemia and ensure high 2,3-DPG levels for oxygen delivery. * **Frozen RBCs:** Can be stored for up to **10 years** using glycerol as a cryoprotectant.
Explanation: ### Explanation **Correct Answer: B. Focal Nodular Hyperplasia (FNH)** **Why it is correct:** Focal Nodular Hyperplasia (FNH) is a benign, non-neoplastic liver lesion typically seen in young to middle-aged women. It is thought to be a hyperplastic response of hepatocytes to a pre-existing **vascular malformation**. The classic gross appearance—which is a high-yield "spotter" for NEET-PG—is a well-demarcated, unencapsulated nodule featuring a **prominent central stellate (star-shaped) fibrous scar**. Radiologically, this scar often shows "delayed enhancement" on CT/MRI. Histologically, the scar contains large anomalous arteries and bile ductular proliferation. **Why incorrect options are wrong:** * **A. Metastatic adenocarcinoma:** Usually presents as multiple, umbilicated (central necrosis) nodules in an older patient with a known primary malignancy (e.g., colon, breast). * **C. Hemangioma:** The most common benign liver tumor. Grossly, it appears as a red-blue, soft, spongy subcapsular mass. It does not typically feature a central stellate scar. * **D. Hepatocellular carcinoma (HCC):** Usually occurs in the setting of cirrhosis or chronic Hepatitis B/C. It often shows vascular invasion, hemorrhage, or necrosis, rather than a clean stellate scar. **High-Yield Clinical Pearls for NEET-PG:** * **FNH vs. Hepatic Adenoma:** Unlike hepatic adenomas, FNH is **not** strongly associated with oral contraceptive pills (OCPs) and has **no risk of malignant transformation** or spontaneous rupture [1]. * **The "Cold" Nodule:** On Sulfur Colloid Scintigraphy (Technetium-99m), FNH often shows normal or increased uptake (because it contains Kupffer cells), whereas most other liver masses appear as "cold" spots. * **Key Gross Feature:** Central stellate scar = FNH. (Note: Fibrolamellar HCC also has a scar, but it is usually seen in adolescents and is malignant). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 398-399.
Explanation: **Explanation:** **Liquefactive necrosis** is characterized by the transformation of the tissue into a liquid, viscous mass. This occurs when the rate of enzymatic digestion of cells exceeds the rate of protein denaturation. **Why the Brain is Correct:** In the Central Nervous System (CNS), ischemic injury (infarct) leads to liquefactive necrosis rather than coagulative necrosis [1]. This is due to two primary reasons: 1. **High Lipid Content:** Brain tissue is rich in lipids and low in supportive connective tissue (collagen). 2. **Hydrolytic Enzymes:** Ischemia triggers the release of potent hydrolytic enzymes from lysosomes (autolysis) and microglial cells, which rapidly dissolve the dead tissue into a fluid-filled cavity [1]. **Analysis of Incorrect Options:** * **A. Heart:** Ischemia of the myocardium leads to **Coagulative Necrosis**. The basic cell outline is preserved for several days as proteins and enzymes are denatured. * **C. Lungs:** While lung infections (like abscesses) can show liquefactive necrosis, an infarct in the lung typically results in **Coagulative Necrosis** (Hemorrhagic/Red Infarct). * **D. Spleen:** Ischemia in solid organs like the spleen results in **Coagulative Necrosis** (Pale/White Infarct). **High-Yield Clinical Pearls for NEET-PG:** * **Two main settings for Liquefactive Necrosis:** 1. Brain Infarcts. 2. Abscesses (due to bacterial or fungal infections where neutrophils release proteolytic enzymes). * **Coagulative Necrosis** is the most common pattern of necrosis and is seen in all solid organ infarcts **except** the brain. * **Wet Gangrene** is a clinical variation of liquefactive necrosis superimposed on coagulative necrosis. * **Morphology:** The necrotic area is eventually removed by phagocytes, leaving a cystic space [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1268-1269.
Explanation: **Explanation:** **Papillary cystadenoma lymphomatosum**, commonly known as **Warthin’s tumour**, is the second most common benign salivary gland neoplasm. The name is derived from its unique histological appearance: it consists of **papillary** projections lined by a double layer of oncocytic cells (columnar and cuboidal) forming **cysts**, all set within a dense **lymphoid** stroma (often containing germinal centers) [1]. **Analysis of Options:** * **Warthin’s tumour (Correct):** It occurs almost exclusively in the **parotid gland** (often in the tail). It is unique because it is the most common salivary gland tumor to present **bilaterally** (10%) or multicentrically [1]. * **Pleomorphic adenoma:** This is the most common salivary gland tumor overall. It is a "mixed tumor" containing both epithelial and mesenchymal elements (chondroid or myxoid stroma), but it lacks the lymphoid-cystic architecture of Warthin’s. * **Mucoepidermoid carcinoma:** This is the most common **malignant** salivary gland tumor. It is composed of a mixture of squamous (epidermoid), mucus-secreting, and intermediate cells. * **Medullary carcinoma:** This is a thyroid malignancy derived from parafollicular C-cells (secreting calcitonin). It is unrelated to salivary gland pathology. **High-Yield Clinical Pearls for NEET-PG:** * **Smoking Link:** Warthin’s tumour has the strongest association with **cigarette smoking** among all salivary tumors (8x higher risk). * **Demographics:** Classically seen in **older males** (though the gender gap is narrowing). * **Imaging:** On Technetium-99m pertechnetate scan, it appears as a **"Hot Nodule"** because the oncocytic cells concentrate the isotope. * **Origin:** It is thought to arise from salivary gland epithelium entrapped within intra-parotid lymph nodes during embryogenesis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, p. 753.
Explanation: **Explanation:** **Dohle bodies** are the correct answer. They are light blue-gray, oval, or teardrop-shaped inclusions found in the cytoplasm of neutrophils. Ultrastructurally, they represent **dilated strands of rough endoplasmic reticulum (RER)**. They are typically seen in "toxic" states such as severe bacterial infections, burns, trauma, or pregnancy, often alongside toxic granulation and cytoplasmic vacuolation. **Analysis of Incorrect Options:** * **Asteroid bodies:** These are star-shaped eosinophilic inclusions found within giant cells in granulomatous diseases, most classically **Sarcoidosis** and Sporotrichosis. * **Bamboo bodies:** These are ferruginous bodies (asbestos bodies) that appear segmented or beaded, resembling bamboo. They are found in the lungs of patients with **Asbestosis**. * **Hirano bodies:** These are eosinophilic, rod-like inclusions made of actin-binding proteins found in the neurons (specifically the hippocampus) of patients with **Alzheimer’s disease**. **High-Yield Clinical Pearls for NEET-PG:** * **May-Hegglin Anomaly:** This is a rare autosomal dominant disorder characterized by large, "Dohle-like" bodies in leukocytes, associated with giant platelets and thrombocytopenia. * **Toxic Granulation:** Often seen with Dohle bodies, these represent prominent primary granules (lysosomes) in neutrophils during inflammation. * **Chediak-Higashi Syndrome:** Characterized by giant lysosomal granules in neutrophils (due to a defect in vesicle trafficking), which should not be confused with Dohle bodies.
Explanation: **Explanation:** The presence of **cholesterol crystals** in a cyst is a hallmark of chronic inflammation, tissue breakdown, or the stagnation of lipid-rich fluids. When cells (like epithelium or blood cells) degenerate, their membranes—which are rich in cholesterol—break down, leading to the precipitation of these crystals [1]. Under a microscope, these appear as characteristic "rhomboid-shaped" or "needle-like" empty spaces (clefts) because the lipid is dissolved during routine histological processing [1]. **Analysis of Options:** * **Branchial Cyst:** These are lymphoepithelial cysts typically found in the neck. They contain a clear or "shimmering" fluid rich in cholesterol crystals, derived from the breakdown of the lymphoid and epithelial lining. * **Dentigerous Cyst (and Odontogenic Keratocysts):** These cysts are associated with the crown of an unerupted tooth. Chronic inflammation within the cyst wall leads to the accumulation of cholesterol crystals, often forming "Rushton bodies" or cholesterol clefts in the stroma. * **Old Hydrocele:** In long-standing (chronic) hydroceles, the fluid becomes thick and turbid. The degeneration of mesothelial cells and blood elements results in a high concentration of cholesterol crystals, giving the fluid a characteristic "gold-leaf" appearance. **NEET-PG High-Yield Pearls:** * **Microscopic Appearance:** Cholesterol crystals are seen as **acicular (needle-shaped) clefts** in H&E sections [1]. * **Cholesteatoma:** Despite the name, it is a keratinizing squamous cyst of the middle ear, but it also frequently contains cholesterol crystals [2]. * **Struma Ovarii:** Can also show cholesterol crystals in the cystic areas. * **Clinical Sign:** Fluid aspirated from these cysts often shows a "shimmering" or "silky" effect when held up to light due to the reflection from the crystals. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 73-74. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 747-748.
Explanation: **Explanation:** **Dystrophic calcification** occurs in **dead, dying, or degenerating tissues** despite normal serum calcium levels and normal calcium metabolism. In **atheromatous plaques**, the necrotic core of the advanced lesion undergoes calcification as a result of cell injury and the accumulation of membrane-bound vesicles (matrix vesicles) that act as a focus for calcium phosphate deposition. **Analysis of Options:** * **Atheromatous plaque (Correct):** This is a classic example of dystrophic calcification. * **Rickets (Incorrect):** This is characterized by a failure of mineralization of the bone matrix due to Vitamin D deficiency, leading to soft bones, not abnormal calcification of tissues. * **Hyperparathyroidism (Incorrect):** This leads to **Metastatic calcification** [1]. High levels of Parathyroid Hormone (PTH) cause hypercalcemia, which results in calcium deposition in previously *normal* tissues (typically the lungs, kidneys, and gastric mucosa) [2]. * **Vitamin A intoxication (Incorrect):** While not a primary cause of calcification, excessive Vitamin D (not A) leads to metastatic calcification. Vitamin A toxicity primarily affects the skin, liver, and CNS. **High-Yield Clinical Pearls for NEET-PG:** * **Dystrophic Calcification:** Serum Calcium is **Normal**; occurs in **damaged** tissue. * **Metastatic Calcification:** Serum Calcium is **Elevated**; occurs in **normal** tissue [1]. * **Psammoma Bodies:** These represent a form of dystrophic calcification seen in **P**apillary thyroid CA, **S**erous cystadenocarcinoma of the ovary, **M**eningioma, and **M**esothelioma (Mnemonic: **PSMM**) [1]. * The first step in dystrophic calcification is the **initiation** (nucleation) of calcium phosphate crystals, often within mitochondria or membrane vesicles. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 127-135. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 76-77.
Explanation: **Explanation:** Apoptosis occurs in two distinct phases: the **Initiation phase**, where caspases become catalytically active, and the **Execution phase**, where these enzymes actually cause cell death [1]. **Why Caspase 3 is correct:** Caspase 3 is the primary **executioner caspase** (along with Caspases 6 and 7). Once activated by either the intrinsic or extrinsic pathway, Caspase 3 cleaves structural proteins (like nuclear lamins) and activates **Cytoplasmic DNase**, leading to the characteristic DNA fragmentation and cytoskeletal breakdown seen in apoptosis. **Analysis of Incorrect Options:** * **Caspase 9 (Option A):** This is the **initiator caspase** for the **Intrinsic (Mitochondrial) pathway** [1]. It is activated after the release of Cytochrome C and the formation of the apoptosome. * **Caspase 8 (Option B):** This is the **initiator caspase** for the **Extrinsic (Death Receptor) pathway** [1]. It is activated by the binding of ligands like FasL to the Fas receptor. * **Caspase 1 (Option C):** This is not involved in classical apoptosis. It is an "inflammatory caspase" involved in **Pyroptosis** and the activation of IL-1̢. **High-Yield Clinical Pearls for NEET-PG:** * **Initiator Caspases:** 8, 9, 10. * **Executioner Caspases:** 3, 6, 7. * **Caspase-Independent Death:** Mediated by AIF (Apoptosis Inducing Factor). * **Marker of Apoptosis:** Annexin V (binds to Phosphatidylserine flipped to the outer membrane). * **DNA Laddering:** A hallmark of apoptosis (180-200 base pair fragments), visualized on gel electrophoresis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-65.
Explanation: **Explanation:** **CD95**, also known as the **Fas receptor**, is a critical mediator of the **Extrinsic (Death Receptor-initiated) Pathway of Apoptosis** [1]. 1. **Why Apoptosis is correct:** CD95 is a surface receptor belonging to the Tumor Necrosis Factor (TNF) receptor family. When CD95 binds to its ligand (FasL), it undergoes trimerization and recruits an adapter protein called FADD (Fas-associated death domain) [1]. This complex, known as the **DISC (Death-Inducing Signaling Complex)**, activates **Caspase-8** (or Caspase-10), which directly triggers the executioner caspase cascade, leading to programmed cell death (apoptosis) [1], [2]. 2. **Why other options are incorrect:** * **Cell Necrosis:** This is an accidental, unregulated form of cell death resulting from severe injury (e.g., ischemia). It involves membrane rupture and inflammation, unlike the receptor-mediated signaling of CD95. * **Interferon activation:** This is primarily associated with antiviral responses and MHC expression, mediated by JAK-STAT signaling pathways, not the Fas/CD95 death receptor. * **Proteolysis:** While apoptosis involves proteolysis (via caspases), CD95 itself is a transmembrane receptor, not a general proteolytic enzyme or a primary regulator of systemic proteolysis. **High-Yield Clinical Pearls for NEET-PG:** * **ALPS (Autoimmune Lymphoproliferative Syndrome):** Caused by mutations in the *Fas* receptor (CD95), *FasL*, or *Caspase-8*. It results in a failure to eliminate self-reactive lymphocytes. * **Caspase-8** is the initiator caspase for the extrinsic pathway; **Caspase-9** is for the intrinsic (mitochondrial) pathway [1]. * **Executioner Caspases:** Caspase-3 and Caspase-6 are common to both pathways. * **Marker:** CD95 is a classic marker used to identify cells primed for apoptosis [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-67. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 310.
Cell Injury and Cell Death
Practice Questions
Adaptations of Cellular Growth
Practice Questions
Accumulations and Deposits
Practice Questions
Acute and Chronic Inflammation
Practice Questions
Tissue Repair and Wound Healing
Practice Questions
Hemodynamic Disorders
Practice Questions
Genetic Disorders
Practice Questions
Environmental Pathology
Practice Questions
Nutritional Diseases
Practice Questions
Molecular Basis of Disease
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free